FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225302710> ?p ?o ?g. }

• W4225302710 endingPage "894" @default.
• W4225302710 startingPage "889" @default.
• W4225302710 abstract "Abstract Background Twenty-four-hour treatment options could provide a continuous drug delivery strategy in advanced Parkinson’s disease and can ameliorate motor and non-motor complications. Use of levodopa infusion is often limited to 12–16 h/day due to its cost. Adjunctive overnight rotigotine transdermal patch is a continuous drug delivery option successfully used in clinical practice coupled with apomorphine infusion. However, real-life data addressing the tolerability of transdermal dopamine agonist therapy with concomitant use of intrajejunal levodopa infusion in advanced Parkinson’s disease are not available. Objective To evaluate the tolerability and beneficial effects of combined therapy with overnight rotigotine transdermal patch and intrajejunal levodopa infusion over a follow-up period of 12 months in advanced Parkinson’s disease. Method In this retrospective data analysis, data before and after the initiation of the continuous drug delivery combined therapy using overnight rotigotine transdermal patch and intrajejunal levodopa infusion were collected from the ongoing non-motor-international-longitudinal study (NILS) and local clinical practice at King’s College Hospital (London, United Kingdom). 12 advanced Parkinson’s disease patients on intrajejunal levodopa therapy who were additionally treated with overnight rotigotine transdermal patch (mean dose 5.67 ± 4.19 mg) are included. Tolerability over a 12-month period was assessed. In addition, changes in motor symptoms (SCales for Outcomes in Parkinson's disease, SCOPA-Motor), non-motor symptoms (Non-Motor Symptoms Scale, NMSS) and quality of life (Parkinson's disease Questionnaire-8, PDQ-8) before and 12-month after continuous drug delivery combined therapy initiation are evaluated. Results Tolerability was 100% irrespective of age, disease duration, stages of disease. (Treatment with overnight rotigotine transdermal patch that was maintained for a minimum of 6 months was considered “tolerated”, primary tolerability). In addition, we noted a significant reduction of the NMSS total score ( p = 0.009) and the NMSS domain 3 score (mood and apathy domain) ( p = 0.028), although the latter did not remain statistically significant after correction for multiple testing ( p 2 = 0.252) at 12 months. Conclusion Combination of intrajejunal levodopa infusion with overnight rotigotine transdermal patch is well tolerated and extend the beneficial effects of infusion with excellent tolerability; and also improved aspects of mood and apathy sustained at 12 months in advanced Parkinson’s disease." @default.
• W4225302710 created "2022-05-05" @default.
• W4225302710 creator A5030504779 @default.
• W4225302710 creator A5032235791 @default.
• W4225302710 creator A5032631400 @default.
• W4225302710 creator A5033436519 @default.
• W4225302710 creator A5046064093 @default.
• W4225302710 creator A5050179468 @default.
• W4225302710 creator A5068457058 @default.
• W4225302710 creator A5084050011 @default.
• W4225302710 date "2022-05-03" @default.
• W4225302710 modified "2023-09-25" @default.
• W4225302710 title "Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease" @default.
• W4225302710 cites W2069005897 @default.
• W4225302710 cites W2092665901 @default.
• W4225302710 cites W2112455323 @default.
• W4225302710 cites W2141713617 @default.
• W4225302710 cites W2161972502 @default.
• W4225302710 cites W2334558638 @default.
• W4225302710 cites W2558736618 @default.
• W4225302710 cites W2757488384 @default.
• W4225302710 cites W2905020308 @default.
• W4225302710 cites W2911619261 @default.
• W4225302710 cites W2980700896 @default.
• W4225302710 cites W3036122209 @default.
• W4225302710 cites W3063250637 @default.
• W4225302710 cites W3126513489 @default.
• W4225302710 cites W3127073955 @default.
• W4225302710 cites W3154889217 @default.
• W4225302710 doi "https://doi.org/10.1007/s00702-022-02506-4" @default.
• W4225302710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35503480" @default.
• W4225302710 hasPublicationYear "2022" @default.
• W4225302710 type Work @default.
• W4225302710 citedByCount "2" @default.
• W4225302710 countsByYear W42253027102022 @default.
• W4225302710 countsByYear W42253027102023 @default.
• W4225302710 crossrefType "journal-article" @default.
• W4225302710 hasAuthorship W4225302710A5030504779 @default.
• W4225302710 hasAuthorship W4225302710A5032235791 @default.
• W4225302710 hasAuthorship W4225302710A5032631400 @default.
• W4225302710 hasAuthorship W4225302710A5033436519 @default.
• W4225302710 hasAuthorship W4225302710A5046064093 @default.
• W4225302710 hasAuthorship W4225302710A5050179468 @default.
• W4225302710 hasAuthorship W4225302710A5068457058 @default.
• W4225302710 hasAuthorship W4225302710A5084050011 @default.
• W4225302710 hasBestOaLocation W42253027101 @default.
• W4225302710 hasConcept C126322002 @default.
• W4225302710 hasConcept C197934379 @default.
• W4225302710 hasConcept C205679159 @default.
• W4225302710 hasConcept C2775842315 @default.
• W4225302710 hasConcept C2778375690 @default.
• W4225302710 hasConcept C2779134260 @default.
• W4225302710 hasConcept C2779424955 @default.
• W4225302710 hasConcept C2779734285 @default.
• W4225302710 hasConcept C2780304432 @default.
• W4225302710 hasConcept C42219234 @default.
• W4225302710 hasConcept C71924100 @default.
• W4225302710 hasConcept C98274493 @default.
• W4225302710 hasConceptScore W4225302710C126322002 @default.
• W4225302710 hasConceptScore W4225302710C197934379 @default.
• W4225302710 hasConceptScore W4225302710C205679159 @default.
• W4225302710 hasConceptScore W4225302710C2775842315 @default.
• W4225302710 hasConceptScore W4225302710C2778375690 @default.
• W4225302710 hasConceptScore W4225302710C2779134260 @default.
• W4225302710 hasConceptScore W4225302710C2779424955 @default.
• W4225302710 hasConceptScore W4225302710C2779734285 @default.
• W4225302710 hasConceptScore W4225302710C2780304432 @default.
• W4225302710 hasConceptScore W4225302710C42219234 @default.
• W4225302710 hasConceptScore W4225302710C71924100 @default.
• W4225302710 hasConceptScore W4225302710C98274493 @default.
• W4225302710 hasIssue "7" @default.
• W4225302710 hasLocation W42253027101 @default.
• W4225302710 hasLocation W42253027102 @default.
• W4225302710 hasLocation W42253027103 @default.
• W4225302710 hasOpenAccess W4225302710 @default.
• W4225302710 hasPrimaryLocation W42253027101 @default.
• W4225302710 hasRelatedWork W1498291894 @default.
• W4225302710 hasRelatedWork W1696672465 @default.
• W4225302710 hasRelatedWork W1975304396 @default.
• W4225302710 hasRelatedWork W2011366475 @default.
• W4225302710 hasRelatedWork W2013095143 @default.
• W4225302710 hasRelatedWork W2038235076 @default.
• W4225302710 hasRelatedWork W2067529168 @default.
• W4225302710 hasRelatedWork W2227696677 @default.
• W4225302710 hasRelatedWork W2461783644 @default.
• W4225302710 hasRelatedWork W4253557999 @default.
• W4225302710 hasVolume "129" @default.
• W4225302710 isParatext "false" @default.
• W4225302710 isRetracted "false" @default.
• W4225302710 workType "article" @default.